Lowering the affinity of single-chain monovalent BBB shuttle scFc-scFv8D3 prolongs its half-life and increases brain concentration

Lowering the affinity of single-chain monovalent BBB shuttle scFc-scFv8D3 prolongs its half-life and increases brain concentration

Monoclonal antibody therapeutics is a massively growing field. Progress in providing monoclonal antibody therapeutics to treat brain disorders is complicated, due to the impermeability of the blood-brain barrier (BBB) to large macromolecular structures. To date, the most successful approach for deli...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrés de la Rosa, Nicole G. Metzendorf, Jonathan Efverström, Ana Godec, Dag Sehlin, Jamie Morrison, Greta Hultqvist
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Neurotherapeutics
Subjects:
Blood brain barrier
Transporter
Antibodies
Affinity
Monovalent
Online Access:http://www.sciencedirect.com/science/article/pii/S187874792400179X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S187874792400179X

Similar Items